|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li Z, Wang Y, Dong S, Ge C, Xiao Y, Li R,
Ma X, Xue Y, Zhang Q, Lv J, et al: Association of CXCR1 and 2
expressions with gastric cancer metastasis in ex vivo and tumor
cell invasion in vitro. Cytokine. 69:6–13. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Choi AH, Nelson RA, Merchant SJ, Kim JY,
Chao J and Kim J: Rates of lymph node metastasis and survival in
T1a gastric adenocarcinoma in Western populations. Gastrointest
Endosc. 83:1184–1192.e1. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhuang K, Han K, Tang H, Yin X, Zhang J,
Zhang X and Zhang L: Up-regulation of plasma miR-23b is associated
with poor prognosis of gastric cancer. Med Sci Monit. 22:356–361.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Thrumurthy SG, Chaudry MA, Chau I and
Allum W: Does surgery have a role in managing incurable gastric
cancer? Nat Rev Clin Oncol. 12:676–682. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ma Z, Ma Y, Xia Q, Li Y, Li R, Chang W,
Chen J, Leng Z and Tao K: MicroRNA-155 expression inversely
correlates with pathologic stage of gastric cancer and it inhibits
gastric cancer cell growth by targeting cyclin D1. J Cancer Res
Clin Oncol. 142:1201–1212. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li C, Deng L, Zhi Q, Meng Q, Qian A, Sang
H, Li X and Xia J: MicroRNA-183 functions as an oncogene by
regulating PDCD4 in gastric cancer. Anticancer Agents Med Chem.
16:447–455. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu D, Zhou Y, Pan H, Zhou J, Fan Y and Qu
P: microRNA-99a inhibiting cell proliferation, migration and
invasion by targeting fibroblast growth factor receptor 3 in
bladder cancer. Oncol Lett. 7:1219–1224. 2014.PubMed/NCBI
|
|
10
|
Katoh M: Cardio-miRNAs and onco-miRNAs:
Circulating miRNA-based diagnostics for non-cancerous and cancerous
diseases. Front Cell Dev Biol. 2:612014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shah NR and Chen H: MicroRNAs in
pathogenesis of breast cancer: Implications in diagnosis and
treatment. World J Clin Oncol. 5:48–60. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fernandez S, Risolino M, Mandia N, Talotta
F, Soini Y, Incoronato M, Condorelli G, Banfi S and Verde P:
miR-340 inhibits tumor cell proliferation and induces apoptosis by
targeting multiple negative regulators of p27 in non-small cell
lung cancer. Oncogene. 34:3240–3250. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liao WT, Ye YP, Zhang NJ, Li TT, Wang SY,
Cui YM, Qi L, Wu P, Jiao HL, Xie YJ, et al: MicroRNA-30b functions
as a tumour suppressor in human colorectal cancer by targeting
KRAS, PIK3CD and BCL2. J Pathol. 232:415–427. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shenouda SK and Alahari SK: MicroRNA
function in cancer: Oncogene or a tumor suppressor? Cancer
Metastasis Rev. 28:369–378. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen CZ: MicroRNAs as oncogenes and tumor
suppressors. N Engl J Med. 353:1768–1771. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu GH, Liu YH, Yang Z, Zhu AL and Zhao
CL: MicroRNA-524-5p suppresses the growth and invasive abilities of
gastric cancer cells. Oncol Lett. 11:1926–1932. 2016.PubMed/NCBI
|
|
18
|
Zhu M, Zhang N, He S, Yan R and Zhang J:
MicroRNA-106a functions as an oncogene in human gastric cancer and
contributes to proliferation and metastasis in vitro and in vivo.
Clin Exp Metastasis. 33:509–519. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang XB, Song L, Wen HJ, Bai XX, Li ZJ
and Ma LJ: Upregulation of microRNA-31 targeting integrin alpha5
suppresses tumor cell invasion and metastasis by indirectly
regulating PI3K/AKT pathway in human gastric cancer SGC7901 cells.
Tumour Biol. 37:8317–8325. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou N, Qu Y, Xu C and Tang Y:
Upregulation of microRNA-375 increases the cisplatin-sensitivity of
human gastric cancer cells by regulating ERBB2. Exp Ther Med.
11:625–630. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Niu G, Li B, Sun J and Sun L: miR-454 is
down-regulated in osteosarcomas and suppresses cell proliferation
and invasion by directly targeting c-Met. Cell Prolif. 48:348–355.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fang B, Zhu J, Wang Y, Geng F and Li G:
MiR-454 inhibited cell proliferation of human glioblastoma cells by
suppressing PDK1 expression. Biomed Pharmacother. 75:148–152. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liang HL, Hu AP, Li SL, Xie JP, Ma QZ and
Liu JY: MiR-454 prompts cell proliferation of human colorectal
cancer cells by repressing CYLD expression. Asian Pac J Cancer
Prev. 16:2397–2402. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sun L, Wang Q, Gao X, Shi D, Mi S and Han
Q: MicroRNA-454 functions as an oncogene by regulating PTEN in
uveal melanoma. FEBS Lett. 589:2791–2796. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yu L, Gong X, Sun L, Yao H, Lu B and Zhu
L: miR-454 functions as an oncogene by inhibiting CHD5 in
hepatocellular carcinoma. Oncotarget. 6:39225–39234. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou L, Qu YM, Zhao XM and Yue ZD:
Involvement of miR-454 overexpression in the poor prognosis of
hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 20:825–829.
2016.PubMed/NCBI
|
|
28
|
Shen A, Zhang Y, Yang H, Xu R and Huang G:
Overexpression of ZEB1 relates to metastasis and invasion in
osteosarcoma. J Surg Oncol. 105:830–834. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Okugawa Y, Toiyama Y, Tanaka K, Matsusita
K, Fujikawa H, Saigusa S, Ohi M, Inoue Y, Mohri Y, Uchida K and
Kusunoki M: Clinical significance of Zinc finger E-box Binding
homeobox 1 (ZEB1) in human gastric cancer. J Surg Oncol.
106:280–285. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jia B, Liu H, Kong Q and Li B:
Overexpression of ZEB1 associated with metastasis and invasion in
patients with gastric carcinoma. Mol Cell Biochem. 366:223–229.
2012. View Article : Google Scholar : PubMed/NCBI
|
